View
212
Download
0
Embed Size (px)
Citation preview
Inpharma 1224 - 12 Feb 2000
■ Interferon (IFN)-β-1a delays the onset of clinicallydefinite multiple sclerosis (MS) in patients who haveexperienced the recent onset of a first demyelinatingevent, report researchers from the CHAMPS* study.383 such patients were randomised to receive IM IFN-β-1a [‘Avonex’] 30µg or placebo, once weekly for ≤ 3years. Results of an interim analysis conducted by theindependent Data Monitoring Committee reveal thatIFN-β-1a, compared with placebo, recipients had asignificantly delayed onset of clinically definite MS,exceeding the pre-established criteria required forearly termination of the trial. Consequently, the trialwill stop early.* Controlled High Risk Subjects Avonex® Multiple SclerosisPrevention Study
Biogen Inc. Biogen’s AVONEX (Rm) (interferon beta-1a) shows a beneficialeffect on delaying the development of multiple sclerosis. Data MonitoringCommittee recommends stopping CHAMPS Trial early; Biogen to apply forbroadened label with regulatory authorities. Media Release : [2 pages], 1 Feb2000. Available from: URL: http://www.biogen.com 800801706
1
Inpharma 12 Feb 2000 No. 12241173-8324/10/1224-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved